Arch Therapeutics holds a total of 249.94 Million outstanding shares. Arch Therapeutics shows 14.58 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in otc stocks such as Arch Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Arch Therapeutics, and when they decide to sell, the otc stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Arch
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Therapeutics. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Arch OTC Stock Ownership Analysis
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.02. Arch Therapeutics had not issued any dividends in recent years. The entity had 1:200 split on the 18th of January 2023. Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.The quote for Arch Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Arch Therapeutics please contact the company at 617 431 2313 or go to https://www.archtherapeutics.com.
Arch Therapeutics Outstanding Bonds
Arch Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arch Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arch bonds can be classified according to their maturity, which is the date when Arch Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Arch Therapeutics financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Therapeutics security.